A Non-interventional Prospective Study of Early HER2-negative High-risk Breast Cancer and BRCA1/2 Mutations Prevalence in RussiA

Study Summary

(Neo)adjuvant treatment approaches and outcomes

Conditions

Breast Cancer

Interventions / Drugs

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment625 participants

Primary Completion—

Lead SponsorAstraZeneca

Data Retrieved2026-04-11 02:55:19.910400+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.